Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 11/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859825 | 0.93 | TAS2R14 (0.56) | TAS2R14LMNAPOLBTP53CNR2 | |
| SCHEMBL3853116 | 0.91 | TAS2R14 (0.62) | TAS2R14LMNAPOLBTP53CNR2 | |
| SCHEMBL3849137 | 0.90 | TAS2R14 (0.55) | TAS2R14LMNATP53CNR2MAPK1 | |
| SCHEMBL3850260 | 0.90 | TAS2R14 (0.57) | TAS2R14LMNATP53CNR2MAPK1 | |
| SCHEMBL3853648 | 0.90 | TAS2R14 (0.57) | TAS2R14LMNATP53CNR2MAPK1 | |
| SCHEMBL3855851 | 0.89 | TAS2R14 (0.54) | TAS2R14LMNAPOLBTP53CNR2 | |
| SCHEMBL3855993 | 0.89 | TAS2R14 (0.59) | TAS2R14LMNAPOLBTP53CNR2 | |
| SCHEMBL3856045 | 0.88 | TAS2R14 (0.61) | TAS2R14LMNATP53MAPK1KCNA5 | |
| SCHEMBL3852854 | 0.88 | TAS2R14 (0.57) | TAS2R14LMNATP53CNR2MAPK1 | |
| SCHEMBL3856017 | 0.87 | TAS2R14 (0.49) | TAS2R14LMNAPOLBTP53CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579504-B2 | ABCA1 elevating compounds | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | claimed |
| US-20070203245-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | claimed |
| US-7579504-B2 | ABCA1 elevating compounds | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070203245-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007067817-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203245-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | TAS2R14 4736/4885LMNA 830/4885POLB 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.